EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Recombinant expression and improved refolding of the SARS-CoV-2 spike receptor-binding domain in Escherichia coli

Daniela Roa-Velázquez, Jessica Georgina Filisola-Villaseñor, Dan Israel Zavala-Vargas, Julio García-Cordero, Noe Juvenal Mendoza-Ramírez, Sandra Paola Martínez-Frías, Gabriel Marcelino-Pérez, Beatriz Xoconostle-Cázares, Leticia Cedillo-Barrón, Martha Espinosa-Cantellano, Edgar Morales-Ríos

Protein Expression and Purification · 2027

DOI: 10.1016/j.pep.2026.106971 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Protein Expression and Purification, 2027. Verfasst von Daniela Roa-Velázquez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Bioquímica, Centro de Investigación y de Estudios Avanzados Del Instituto Politécnico Nacional, Av. IPN 2508, Ciudad de México, 07360…. Hauptthemen laut MEDLINE: Escherichia coli, Spike Glycoprotein, Coronavirus, SARS-CoV-2, COVID-19. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AMEXCID, SECIHTI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The receptor-binding domain (RBD) of SARS-CoV-2 spike glycoprotein is central to serological diagnostics and vaccine development, but production in eukaryotic expression systems is costly and technically demanding. Here, we describe an Escherichia coli platform to express the wild-type RBD, used as an initial model for the standardization of the methodology. Subsequently, the platform was applied to the alpha and beta variants, demonstrating its adaptability to different RBD variants. Inclusion bodies were purified under denaturing conditions and refolded by size-exclusion chromatography using a linear urea gradient and a redox/anti-aggregation buffer that promotes correct disulfide-bond formation and minimizes aggregation. The procedure yielded ∼36 mg of soluble protein per liter of culture. The refolded recombinant RBDs of wild-type, alpha and beta variants, as well as RDB wild-type produced in Expi293 cells as a control were evaluated in ELISA assays against sera from healthy, vaccinated and convalescent SARS-CoV-2 patients. All recombinant RBDs produced in E. coli were recognized by patients' sera, demonstrating that they retain antigenicity and supporting their use in serological assays as a rapid and scalable source of antigens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Escherichia coliSpike Glycoprotein, CoronavirusSARS-CoV-2COVID-19Recombinant ProteinsHumansProtein RefoldingProtein DomainsInclusion BodiesAntibodies, ViralChromatography, GelGene Expression

Stichwörter der Autor:innen

COVID-19IgG detectionInclusion bodiesRecombinant RBDSARS-CoV-2Size-exclusion chromatography

Substanzen

Spike Glycoprotein, CoronavirusRecombinant Proteinsspike protein, SARS-CoV-2Antibodies, Viral

Autor:innen und Institutionen

  • Departamento de Bioquímica, Centro de Investigación y de Estudios Avanzados Del Instituto Politécnico Nacional, Av. IPN 2508, Ciudad de México, 07360, Mexico. Electronic address: daniela.roa@cinvestav.mx.
  • Departamento de Bioquímica, Centro de Investigación y de Estudios Avanzados Del Instituto Politécnico Nacional, Av. IPN 2508, Ciudad de México, 07360, Mexico. Electronic address: jessica.filisola@cinvestav.mx.
  • Departamento de Bioquímica, Centro de Investigación y de Estudios Avanzados Del Instituto Politécnico Nacional, Av. IPN 2508, Ciudad de México, 07360, Mexico. Electronic address: danisraelz@gmail.com.
  • Departamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados Del Instituto Politécnico Nacional, Av. IPN 2508, Ciudad de México, 07360, Mexico. Electronic address: jugarcia@cinvestav.mx.
  • Departamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados Del Instituto Politécnico Nacional, Av. IPN 2508, Ciudad de México, 07360, Mexico. Electronic address: noe.mendoza@cinvestav.mx.
  • Departamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados Del Instituto Politécnico Nacional, Av. IPN 2508, Ciudad de México, 07360, Mexico. Electronic address: sandrapaola_mtzf@yahoo.com.mx.

Förderung

  • AMEXCID
  • SECIHTI

Zitieren

APA

Roa-Velázquez, D., Filisola-Villaseñor, J. G., Zavala-Vargas, D. I., García-Cordero, J., Mendoza-Ramírez, N. J., Martínez-Frías, S. P., Marcelino-Pérez, G., Xoconostle-Cázares, B., Cedillo-Barrón, L., Espinosa-Cantellano, M., & Morales-Ríos, E. (2027). Recombinant expression and improved refolding of the SARS-CoV-2 spike receptor-binding domain in Escherichia coli. Protein Expression and Purification. https://doi.org/10.1016/j.pep.2026.106971

Vancouver

Roa-Velázquez D, Filisola-Villaseñor JG, Zavala-Vargas DI, García-Cordero J, Mendoza-Ramírez NJ, Martínez-Frías SP, et al. Recombinant expression and improved refolding of the SARS-CoV-2 spike receptor-binding domain in Escherichia coli. Protein Expression and Purification. 2027. doi:10.1016/j.pep.2026.106971

BibTeX
@article{RoaVelzquez2027,
  author = {Roa-Velázquez, Daniela and Filisola-Villaseñor, Jessica Georgina and Zavala-Vargas, Dan Israel and García-Cordero, Julio and Mendoza-Ramírez, Noe Juvenal and Martínez-Frías, Sandra Paola and Marcelino-Pérez, Gabriel and Xoconostle-Cázares, Beatriz and Cedillo-Barrón, Leticia and Espinosa-Cantellano, Martha and Morales-Ríos, Edgar},
  title = {Recombinant expression and improved refolding of the SARS-CoV-2 spike receptor-binding domain in Escherichia coli},
  journal = {Protein Expression and Purification},
  year = {2027},
  doi = {10.1016/j.pep.2026.106971}
}
Kostenlos starten →